Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-02-11T10:08:09.952Z Has data issue: false hasContentIssue false
  • English
  • Français

A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities – Erratum

Published online by Cambridge University Press:  17 May 2022

Valentine Grumberg ,
Stéphane Roze ,
Julie Chevalier ,
John Borrill ,
Anne-Françoise Gaudin  and
Sébastien Branchoux
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Correction
Information
International Journal of Technology Assessment in Health Care , Volume 38 , Issue 1 , 2022 , e38
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press

In the original publication of Grumberg et al. (Reference Grumberg, Roze, Chevalier, Borrill, Gaudin and Branchoux2022) a typesetting error occurred in Table 2. The correct Table 2 is reproduced below.

Table 2. Best-Fit and Second Best-Fit Models to OS Kaplan–Meier Curves with at least 18-Month Extended Follow-up

Abbreviations: HR: hazard ratio; KM: Kaplan-Meier; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; RMST: restricted mean survival time; UC: urothelial cancer.

The publisher apologizes for this error.

References

Grumberg, V., Roze, S., Chevalier, J., Borrill, J., Gaudin, A., & Branchoux, S. (2022). A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care, 38(1), E28. doi:10.1017/S0266462322000125CrossRefGoogle ScholarPubMed
Figure 0

Table 2. Best-Fit and Second Best-Fit Models to OS Kaplan–Meier Curves with at least 18-Month Extended Follow-up